Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)

NCT03172494 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT03172494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03172494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
May 26, 2017
Completion date
July 13, 2019
Enrollment
720 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2